Evidence map›Paper›PMID 28480306›Full record

ReviewMolecular therapy. Methods & clinical development2017

Dendritic Cell Therapies for Hematologic Malignancies.

Matthew Weinstock, Jacalyn Rosenblatt, David Avigan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular therapy. Methods & clinical development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Vaccines: a promising therapy for myelodysplastic syndrome.Journal of hematology & oncology · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Increasing Role of Targeted Immunotherapies in the Treatment of AML.International journal of molecular sciences · 2022
    Review
  14. Review
  15. Review
  16. Review
  17. Calreticulin as an AdjuvantJournal of immunology research · 2022
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Matthew WeinstockBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Jacalyn RosenblattBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.
David AviganBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Beth Israel Deaconess Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells that constitute a major component of the immune system's role in the recognition, elimination, and tolerance of cancer. The unique immunologic capabilities of DCs have recently been harnessed for therapeutic use with the creation of DC-based anti-tumor vaccines, several of which have moved into testing in clinical trials for hematologic malignancies. This review summarizes how treatment strategies using DC-based anti-tumor vaccines are advancing immunotherapeutic options for these diseases.

Indexed as

AMLcancer immunotherapydendritic cellmultiple myelomatumor immunologyvaccine

Identifiers

PMID28480306
PMCPMC5415319
OpenAlexW2594967879

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.